Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures – SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral...
A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology
BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients suffering from atrial fibrillation (AF) in a groundbreaking study using a next-generation catheter designed to improve the way AF is treated. PRAGUE, Dec. 3, 2024 /PRNewswire/ -- As the prevalence of atrial fibrillation (AF) continues to rise, BTL has announced...
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESG actions among suppliers. Second of its kind, the event was held virtually to invite more domestic...
Riyadh International Philosophy Conference 2024: Bigger and bolder in its fourth edition
Over 60 renowned philosophers and thinkers to join Riyadh's leading intellectual platform to explore "Philosophy and Quality of Life: Existence, Truth, and Goodness" RIYADH, Saudi Arabia, Dec. 3, 2024 /PRNewswire/ -- The Riyadh International Philosophy Conference 2024 is gearing up for its fourth and largest edition yet. Scheduled to take place from...
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO"), effective December...
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis
– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics – SHANGHAI, Dec. 3, 2024 /PRNewswire/ -- InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis. The randomized, multicenter, double-blind, placebo-controlled...
AC Health makes critical HIV care more accessible to Filipinos with USAID support
MANILA, Philippines, Dec. 3, 2024 /PRNewswire/ -- Ayala Healthcare Holdings, Inc. (AC Health), in partnership with the U.S. Agency for International Development (USAID), is leading the private sector's efforts to fight the HIV epidemic in the Philippines by improving access to stigma-free care and lifesaving services. ...
ZEISS Debuts MYO 200 Biometer for Myopia Management in Hong Kong, Built on ZEISS “Gold Standard” Technology to Safeguard the Visual Health of Children and Adolescents
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Global optical technology leader ZEISS debuted the ZEISS MYO 200 Biometer for Myopia Management in Hong Kong on November 28th, to provide more precise myopia control and improved visual health for children and adolescents. Specifically tailored for children and adolescents, MYO 200 features enhanced accuracy and convenience using ZEISS's key optical technologies, supporting eye...
Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine – helping to fight against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia, – is now approved for infants, children and adolescents from 6 weeks to...
HKBU scientist’s Automated Multiplex Diagnostics System recommended by WHO as an innovative health technology for low-resource contexts
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- The Automated Multiplex Diagnostics System developed by Professor Terence Lau, Interim Chief Innovation Officer of Hong Kong Baptist University (HKBU), has been recommended in the 2024 Compendium of Innovative Health Technologies for Low-resource Settings published by the World Health Organization (WHO) as an innovative technology with the potential to contribute positively to health systems...
